Free tool
Oncology stocks
We cover 15 companies grouped under the Oncology theme. The median market value in the group is $753.78M. Across the group, the median move over the past trading day is +0.14%. Price change over the past year runs from −15.9% to +390.5% across the middle 80 percent of the group, with a median of +53.5%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
15 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0J9P.L | Incyte Corporation | $21.10B | Large cap | +53.49% |
| GE9.DE | Genmab A/S | $20.65B | Large cap | −11.12% |
| 0M2N.L | Orion Oyj | $11.16B | Large cap | +20.48% |
| VIR | Vir Biotechnology, Inc. | $1.87B | Small cap | +111.85% |
| INBX | Inhibrx Biosciences, Inc. | $1.81B | Small cap | +357.45% |
| CGEM | Cullinan Therapeutics, Inc. | $1.48B | Small cap | +188.15% |
| JANX | Janux Therapeutics, Inc. | $1.15B | Small cap | −19.10% |
| 4588.T | Oncolys BioPharma Inc. | $753.78M | Small cap | +539.50% |
| 0SZI.L | Corbus Pharmaceuticals Holdings, Inc. | $707.84M | Small cap | +9.60% |
| SGMT | Sagimet Biosciences Inc. | $675.04M | Small cap | +39.59% |
| PRLD | Prelude Therapeutics Incorporated | $522.47M | Small cap | +412.50% |
| 0LOV.L | Verastem, Inc. | $470.33M | Small cap | −19.93% |
| 0XOD.L | UroGen Pharma Ltd. | $347.24M | Small cap | +136.88% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $218.56M | Small cap | +7.93% |
| ASRT | Assertio Holdings Inc | $151.86M | Small cap | +103.46% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.